Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BROMOCRIPTINE MESYLATE vs ACTIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bromocriptine mesylate is a dopamine D2 receptor agonist that also exhibits partial agonist activity at D1 receptors. By stimulating dopamine receptors in the tuberoinfundibular pathway, it inhibits prolactin secretion from the anterior pituitary. It also activates postsynaptic dopamine receptors in the striatum, improving motor function in Parkinson disease. Additionally, it has been shown to improve glycemic control in type 2 diabetes by modulating central dopaminergic tone and reducing hepatic glucose production.
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
FDA-approved: Treatment of hyperprolactinemia (including amenorrhea/galactorrhea, hypogonadism, infertility) associated with prolactin-secreting adenomas,FDA-approved: Adjunctive treatment of Parkinson disease (idiopathic or postencephalitic),FDA-approved: Treatment of acromegaly (as an adjunct to surgery or radiotherapy),Off-label: Type 2 diabetes mellitus (improves glycemic control),Off-label: Neuroleptic malignant syndrome,Off-label: Prevention of postpartum lactation (use not recommended due to serious adverse events)
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
Oral: 1.25-2.5 mg twice daily, increased gradually as tolerated. Maximum 100 mg/day. Also used intravaginally for hyperprolactinemia (2.5 mg once daily).
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
Terminal elimination half-life is approximately 6-8 hours in healthy individuals, but may be prolonged to 12-14 hours in patients with hepatic impairment or in the elderly.
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Extensively metabolized primarily by cytochrome P450 3A4 (CYP3A4) to multiple metabolites, including the major active metabolite 2-bromo-α-ergocriptine. Also undergoes non-CYP-mediated hydrolysis and conjugation. First-pass metabolism is significant, resulting in ~6% oral bioavailability.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Primarily hepatic metabolism with 85-90% fecal excretion via bile; <5% renal excretion as unchanged drug and metabolites.
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
90-96% bound to serum albumin, with some binding to alpha-1-acid glycoprotein.
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
Approximately 2-3 L/kg, indicating extensive tissue distribution and penetration into breast milk and central nervous system.
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Oral: 28-30% due to extensive first-pass metabolism; sublingual: 40-50% due to partial avoidance of hepatic first-pass; rectal: approximately 20%.
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
No specific dose adjustment recommended; monitor for accumulation in severe renal impairment (e GFR <30 m L/min).
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
Child-Pugh A: No adjustment; Child-Pugh B: Reduce dose by 50%; Child-Pugh C: Avoid use.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
Prolactinomas: 1.25-2.5 mg/m²/day orally in 2-3 divided doses; titrate based on response. Weight-based: 0.01-0.02 mg/kg/day, increase slowly.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
Initiate at low end of dosing range (1.25 mg once or twice daily) due to increased sensitivity and risk of hypotension; titrate slowly.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
None
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
May cause hypotension (especially postural), syncope, and severe adverse reactions such as myocardial infarction, stroke, seizures, and psychosis. Can cause pleural and retroperitoneal fibrosis, pericarditis, and valvulopathy (especially with high doses for Parkinson disease). Has been associated with pathological gambling, hypersexuality, and impulse control disorders. May cause somnolence and sudden sleep onset. Monitor for cardiac valvulopathy and pulmonary fibrosis. Use with caution in patients with cardiovascular disease, peptic ulcer disease, or a history of mental illness.
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Absolute: Hypersensitivity to bromocriptine or ergot alkaloids; uncontrolled hypertension; pregnancy (toxemia of pregnancy); preeclampsia/eclampsia; coronary artery disease or other significant cardiovascular disease; severe renal or hepatic impairment. Relative: History of peptic ulcer disease, psychiatric disorders, Raynaud phenomenon, or hepatic impairment.
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
Take with food to reduce gastrointestinal irritation; avoid high-protein meals if using for hyperprolactinemia as protein may decrease absorption.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
First trimester: Limited human data; animal studies show increased fetal resorption and growth retardation at high doses. Second and third trimesters: Risk of postpartum hemorrhage due to uterine atony; may suppress pituitary prolactin, potentially impairing placental lactogen production. Overall, use only if clearly needed.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Bromocriptine suppresses lactation by inhibiting prolactin secretion. It is contraindicated in breastfeeding women due to the intended suppression of milk production. No M/P ratio available; minimal excretion into breast milk is expected but not well studied.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
No specific dose adjustments are recommended for pregnancy; however, the drug is generally discontinued once pregnancy is confirmed unless necessary for prolactinoma treatment. Pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) may theoretically alter levels, but data are insufficient to recommend dose changes.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
Titrate slowly to minimize orthostatic hypotension and gastrointestinal upset. Administer with food to reduce nausea. Monitor for pulmonary fibrosis and Raynaud phenomenon with long-term use. Avoid concomitant use with ergot alkaloids due to additive vasospasm risk.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
Take with food to reduce nausea and lightheadedness.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Avoid alcohol as it may worsen side effects.,Report persistent cough, chest pain, or changes in urination or vision.,Do not stop abruptly; taper under medical supervision.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
"Coadministration of bromocriptine, a dopamine D2 receptor agonist with vasoconstrictive properties, and ergometrine, an ergot alkaloid that acts as a partial agonist at alpha-adrenergic and serotonin receptors, synergistically increases peripheral vasoconstriction. This additive effect can lead to severe hypertension, myocardial ischemia, cerebral vasospasm, and potentially life-threatening ergotism. Patients may present with headache, chest pain, altered mental status, or peripheral ischemia."
"Concurrent use of bromocriptine, a dopamine D2 receptor agonist, and enasidenib, an IDH2 inhibitor, may lead to increased risk of central nervous system adverse effects, including dizziness, somnolence, and extrapyramidal symptoms. Enasidenib inhibits CYP3A4, which metabolizes bromocriptine, potentially elevating bromocriptine plasma concentrations. This pharmacokinetic interaction can exacerbate dopaminergic toxicity, especially in patients with hepatic impairment or those on high-dose bromocriptine."
"Bromocriptine, a dopamine D2 receptor agonist and ergot derivative, is primarily metabolized by CYP3A4. Astemizole, a second-generation antihistamine, is also metabolized by CYP3A4. Concomitant use of these two drugs can lead to competitive inhibition of CYP3A4, resulting in increased plasma concentrations of both agents. Elevated bromocriptine levels raise the risk of ergotism (vasospasm, ischemia) and neuropsychiatric toxicities, while increased astemizole concentrations may prolong the QT interval, predisposing patients to life-threatening ventricular arrhythmias such as torsades de pointes."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BROMOCRIPTINE MESYLATE vs ACTIQ, answered by our medical review team.
BROMOCRIPTINE MESYLATE is a Dopamine Agonist that works by Bromocriptine mesylate is a dopamine D2 receptor agonist that also exhibits partial agonist activity at D1 receptors. By stimulating dopamine receptors in the tuberoinfundibular pathway, it inhibits prolactin secretion from the anterior pituitary. It also activates postsynaptic dopamine receptors in the striatum, improving motor function in Parkinson disease. Additionally, it has been shown to improve glycemic control in type 2 diabetes by modulating central dopaminergic tone and reducing hepatic glucose production.. ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BROMOCRIPTINE MESYLATE and ACTIQ depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BROMOCRIPTINE MESYLATE is: Oral: 1.25-2.5 mg twice daily, increased gradually as tolerated. Maximum 100 mg/day. Also used intravaginally for hyperprolactinemia (2.5 mg once daily).. The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BROMOCRIPTINE MESYLATE and ACTIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BROMOCRIPTINE MESYLATE is classified as Category A/B. First trimester: Limited human data; animal studies show increased fetal resorption and growth retardation at high doses. Second and third trimesters: Risk of postpartum hemorrhage. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.